ABiC targets all sites of outflow resistanceAb-interno canaloplasty (ABiC) is a minimally invasive glaucoma surgery that accesses, catheterizes, and viscodilates all sites controlling aqueous outflow. When performed alone for uncontrolled glaucoma or with cataract surgery, it can result in reduced IOP and daily medication at follow-up through 12 months.
In this issue
Glaucoma may not be the disease you think it is August 01, 2016By Fred GebhartClinicians continue to explore the relationship between IOP and cerebrospinal fluid pressure in glaucoma. Portable device offers rapid high-definition meibomian gland imaging August 01, 2016By Nancy GrovesA new compact, portable device for rapid, high-definition meibomian gland imaging (LipiScan, TearScience) is an efficient screening tool for patients with complaints of dry eye and/or candidates for surgical procedures in which pre-existing dry eye could affect outcomes. Getting ready for ARVO 2017: New president, special OCT issue August 01, 2016By Katrina NorfleetLearn about the latest updates from The Association for Research in Vision and Ophthalmology for 2017 and beyond. Ophthalmology and death by poisonMy position is that murdering people with poison is a terrible thing, even if the victim is an annoying parent, mother-in-law, or department chair. It's morally wrong, plus the penalty would likely be severe (suspension of operating privileges or even being fired—unless, of course, you have tenure). Yet ophthalmologists certainly have the means to go around poisoning folks. Aqueous drainage tube provides trabeculectomy-like efficacyIn a study including 23 eyes with a transscleral micro-lumen aqueous drainage tube after failing maximum tolerated medication, reductions in the mean IOP were observed as well as in the mean number of medications per day. Multiple next-generation stents lead to better IOP control August 01, 2016By Vanessa CaceresThe use of multiple second-generation stent systems led to a 20% or higher reduction in IOP in a group of patients with mild-to-moderate, open-angle glaucoma. Cyclophotocoagulation shows safety in glaucoma case seriesCharles L. Harris, MD, reviews safety and efficacy rates in a glaucoma case series after adding a proprietary laser system with probe to the surgical armamentarium. CO2 laser-assisted procedure showing long-term efficacy, safetyCO2 laser-assisted sclerectomy performed with a proprietary laser system is a simplified filtration procedure that is showing good IOP-lowering efficacy and safety in eyes followed to 5 years. Second pivotal trial confirms IOP-lowering efficacy of first-in-class agentResults from a second pivotal trial investigating latanoprostene bunod 0.024% (LBN) are consistent with another identically designed study showing that not only is LBN non-inferior to timolol maleate 0.5% for lowering IOP, but it has significantly greater efficacy. Novel gelatin stent works effectively as stand-alone procedure August 01, 2016By Fred GebhartOne-year results are reviewed for use of a novel ab-interno gelatin stent as a stand-alone procedure for patients with mild-to-moderate primary open-angle glaucoma. New dual blade can help surgeons lower IOP August 01, 2016By Vanessa CaceresA new trabecular meshwork excision blade takes a new approach in IOP reduction. Bimatoprost sustained-release implants: Potential new pathway for glaucoma patients August 01, 2016By Lynda ChartersThe bimatoprost sustained-release implant (bimatoprost SR, Allergan) improves compliance for patients with problematic compliance with topical IOP-lowering glaucoma drugs and controlled the IOP for 6 months after injection.